tradingkey.logo

Utah Medical's Q2 revenue falls on lower PendoTECH sales

ReutersJul 24, 2025 1:10 PM


Overview

  • Utah Medical Q2 2025 revenue falls 4.3% yr/yr, driven by lower PendoTECH sales

  • Company's gross profit margin contracts due to lower sales, unfavorable product mix

  • Share repurchases help mitigate EPS decline despite revenue and profit challenges


Outlook

  • Company expects 2H 2025 PendoTECH sales to be $200 lower than 2H 2024

  • Utah Medical projects 2025 sales to PendoTECH $2 mln lower than 2024


Result Drivers

  • PENDOTECH SALES DECLINE - Major driver of revenue drop with sales $315 lower in Q2 2025 compared to Q2 2024

  • UNFAVORABLE PRODUCT MIX - Gross profit margin contracted due to lower sales and product mix issues in Ireland

  • LITIGATION COST REDUCTION - Operating income decline was less severe due to $355 lower litigation costs in Q2 2025


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q2 Sales

$9.95 mln

Q2 EPS

$0.94

Q2 Net Income

$3.05 mln

Q2 Gross Profit

$5.60 mln

Q2 Operating Income

$3.20 mln

Q2 Pretax Profit

$3.84 mln

Press Release: ID:nACSxzpHca

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI